Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

被引：0
|
作者：
Jasmeet Chadha Singh
Yelena Novik
Stacey Stein
Matthew Volm
Marlene Meyers
Julia Smith
Coral Omene
James Speyer
Robert Schneider
Komal Jhaveri
Silvia Formenti
Victoria Kyriakou
Benson Joseph
Judith D Goldberg
Xiaochun Li
Sylvia Adams
Amy Tiersten
机构：
[1] New York University Medical Center,Department of Medicine, Division of Hematology
[2] New York University Cancer institute,Oncology
[3] Yale Medical Center,Department of Medicine, Division of Hematology
[4] New York University Medical Center,Oncology
[5] NYU Cancer Institute,Department of Radiation Oncology
[6] New York University School of Medicine,Clinical trials office
[7] Mt Sinai School of Medicine,Division of Biostatistics
[8] Mt Sinai School of Medicine,Department of Medicine, Division of Hematology
来源：
Breast Cancer Research | / 16卷
关键词：
Trastuzumab; Carboplatin; Cetuximab; International Normalize Ratio; Everolimus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.
    Moreno-Aspitia, A.
    Rowland, K. M.
    Liu, H.
    Hillman, D. W.
    Stella, P. J.
    Perez, E. A.
    CANCER RESEARCH, 2011, 71
  • [32] Immunogenicity of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple negative breast cancer
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Ge, Xuan
    Lee, Jin Sun
    Frankel, Paul H.
    Cui, Yujie
    Ruel, Christopher
    Schmolze, Daniel
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Lee, Peter
    Waisman, James
    Yuan, Yuan
    CANCER RESEARCH, 2023, 83 (05)
  • [33] Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer
    Chan, Arlene
    Moylan, Eugene
    Jackson, Sally
    Devoto, Jeannette
    Jones, Nicola
    Radmil, Silvie
    Wilkinson, Kate
    Roohullah, Aflah
    Adam, Tamiem
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin-San
    CANCER RESEARCH, 2021, 81 (04)
  • [34] Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
    O'Shaughnessy, Joyce
    Schwartzberg, Lee
    Danso, Michael A.
    Miller, Kathy D.
    Rugo, Hope S.
    Neubauer, Marcus
    Robert, Nicholas
    Hellerstedt, Beth
    Saleh, Mansoor
    Richards, Paul
    Specht, Jennifer M.
    Yardley, Denise A.
    Carlson, Robert W.
    Finn, Richard S.
    Charpentier, Eric
    Garcia-Ribas, Ignacio
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) : 3840 - U232
  • [35] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Lander, Eric Michael
    Lehmann, Brian David
    Shah, Payal D.
    Dees, Elizabeth Claire
    Ballinger, Tarah Jean
    Pohlmann, Paula Raffin
    Santa-Maria, Cesar Augusto
    Shyr, Yu
    Mayer, Ingrid A.
    Park, Ben Ho
    Pietenpol, Jennifer A.
    Abramson, Vandana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer
    Meng, Yanchun
    Jin, Juan
    Gong, Chengcheng
    Miao, Haitao
    Tao, Zhonghua
    Li, Ting
    Cao, Jun
    Wang, Leiping
    Wang, Biyun
    Zhang, Jian
    Hu, Xichun
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11255 - 11264
  • [37] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03): : E382 - E393
  • [38] A multicentered randomized phase II comparison of single-agent carboplatin versus the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer.
    Fukui, Jami Aya
    Shapiro, Charles L.
    Ru, Meng
    Klein, Paula
    Fasano, Julie
    Bhardwaj, Aarti
    Irie, Hanna
    Mandeli, John P.
    Goel, Anupama
    Kumarley, Neha
    Gomes, Joni
    Shuman, Nicholas
    Francois, Damien
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] A phase 1/2 of a combination of Cetuximab and Taxane for "triple negative" breast cancer patients
    Nechushtan, Hovav
    Vainer, Gilad
    Stainberg, Hana
    Salmon, Asher Y.
    Hamburger, Tamar
    Peretz, Tamar
    BREAST, 2014, 23 (04): : 435 - 438
  • [40] A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)
    Damodaran, Senthil
    Liu, Diane
    Schwartz, Jill
    Valero, Vicente
    Ramirez, David
    Saleem, Sadia
    Ueno, Naoto T.
    Ibrahim, Nuhad K.
    Karuturi, Meghan S.
    Murthy, Rashmi K.
    Moulder, Stacy
    Litton, Jennifer K.
    CANCER RESEARCH, 2023, 83 (05)
12345